Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.

× No keyword cloud information.

7 in total

1. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.

Authors: Satoshi Morishige; Marina Nishi; Hiroshi Saruta; Fumiko Arakawa; Yoshitaka Yamasaki; Shuki Oya; Takayuki Nakamura; Ritsuko Seki; Maki Yamaguchi; Kazutoshi Aoyama; Fumihiko Mouri; Koichi Osaki; Koichi Ohshima; Koji Nagafuji
Journal: Int J Hematol Date: 2019-05-31 Impact factor: 2.490

Review 2. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

Authors: Louise Photiou; Carrie van der Weyden; Christopher McCormack; H Miles Prince
Journal: Curr Oncol Rep Date: 2018-03-23 Impact factor: 5.075

3. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.

Authors: Kenji Ishitsuka; Satoshi Yurimoto; Kouichi Kawamura; Yukie Tsuji; Manabu Iwabuchi; Takeshi Takahashi; Kensei Tobinai
Journal: Int J Hematol Date: 2017-06-09 Impact factor: 2.319

Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient.

1. Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia/lymphoma after haploidentical stem cell transplantation.

Review 2. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

3. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.

4. Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy.

5. New Targeted Treatments for Cutaneous T-cell Lymphomas.

Review 6. Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas.

Review 7. Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.